Ginkgo bioworks acquires patch biosciences, expanding suite of genetic medicine capabilities available to customers

Boston , feb. 28, 2024 /prnewswire/ -- today, ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, announced the acquisition of patch biosciences , which has built an ai platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by andreessen horowitz (a16z) bio + health, casdin capital, and s32. the acquisition is intended to strengthen ginkgo's gene therapy services , cell therapy services , and rna therapeutics services.
DNA Ratings Summary
DNA Quant Ranking